RxDoctor Payments Data

Ellison Smith, MD

Rheumatology · Asheville, NCNPI 1538123989

Payments from drug & device makers

$1,173in general payments, 2019–2025

Across 53 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$302
  • E.r. Squibb & Sons, L.L.C.$205
  • AbbVie$204
  • Novartis$196
  • Pfizer$109
  • UCB, Inc.$68
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$1,173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 30th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,715,519
Medicare patients
451
Services billed
194,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept101$845,038
Humira(Cf) PenAdalimumab66$601,026
SimponiGolimumab76$467,738
Xeljanz XrTofacitinib Citrate67$391,486
EnbrelEtanercept42$373,935
RinvoqUpadacitinib35$225,940
Cimzia (2 Pack)Certolizumab Pegol22$193,591
Orencia ClickjectAbatacept21$118,006
Cosentyx (2 Syringes)Secukinumab12$90,208
OtezlaApremilast13$63,928
KevzaraSarilumab12$60,637
ActemraTocilizumab18$59,015
Actemra ActpenTocilizumab11$52,722
Hydroxychloroquine Sulfate564$23,363
MethotrexateMethotrexate Sodium571$15,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$302$437,86355 claims
AbbVieRinvoq$204$225,94035 claims
UCB, Inc.Cimzia (2 Pack)$68$193,59122 claims
NovartisCosentyx (2 Syringes)$196$90,20812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →